Kiniksa pointed to Arcalyst's success with its most recent approval, specifically for heart disorder pericarditis, as the ...
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported first-quarter 2026 results and provided updates on commercial ...
Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent ...
Kiniksa Pharmaceuticals (KNSA) reached a 52-week high on Tuesday after the company reported better-than-expected Q1 2026 and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Guidance and language shifted from reiterating 2026 net revenue guidance of $900 million to $920 million to raising it to $930 million to $945 million, attributed to Q1 prescribing breadth/depth.
Kiniksa raised its 2025 ARCALYST net sales guidance to $625 million to $640 million, up from prior guidance of $590 million to $605 million. This reflects management's confidence in continued growth ...
Kiniksa Pharmaceuticals' stock surged nearly 24% after its first-quarter 2026 earnings topped analyst expectations, fueled by ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results